Enterprise Value
415.4M
Cash
562.3M
Avg Qtr Burn
-34.71M
Short % of Float
8.82%
Insider Ownership
0.71%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Pegozafermin (BIO89-100) (FGF21 analog) Details Non-alcoholic steatohepatitis | Phase 3 Data readout | |
Pegozafermin (BIO89-100) (FGF21 analog) Details metabolic dysfunction-associated steatohepatitis | Phase 3 Data readout | |
Pegozafermin (BIO89-100) (FGF21 analog) Details Severe hypertriglyceridemia | Phase 3 Data readout |